Some, but not all studies have reported a positive effect of aminobisphosphonates on atherosclerotic lesions. However, no convincing explanations exist regarding this finding. Recently it has been reported that the levels of FGF23 are positively related to the progression of atherosclerosis and to the calcification of atherosclerosis plaque. Sixty postmenopausal osteoporotic women (mean age: 66.4 ± 7.6 years), not previously treated with drugs for osteoporosis and with normal levels of 25OHvitamin D, were randomly allocated to receive zoledronate 5 mg i.v. annually or ibandronate 3 mg i.v. every 3 months. At baseline and at month 12 we measured serum lipids, bone isoenzyme of alkaline phosphatase, parathyroid hormone, 25-hydroxy-vitamin D, the terminal fragment of collagen type 1, the fibroblast growth factor-23 (FGF23) and osteocalcin. Patients with impaired renal function were excluded from the study. Bone Mineral Density (BMD) at lumbar spine and at femur (neck and total sub regions) and total body were also measured (DXA method, Prodigy GE Lunar, USA). An ultrasound examination of carotid vessels was performed to assess intima-media-thickness (IMT), presence of plaque and the degree of calcification. Patients with atherosclerotic plaques were found to have significantly lower BMD values (p <0.05) than those without plaques. Serum levels of FGF23 were reduced in osteoporotic women who presented with carotid plaques but without reaching any statistical significance (26.6 ? 14.6 vs 18.9 ? 8.1 RU/ml). Also serum levels of osteocalcin were reduced in women with carotid plaques (4.3 ? 2.5 vs 4.7 ? 1.2 ng/ml; p=n.s.). Both FGF23 and osteocalcin were negatively correlate with IMT (r =-0.42 p <0.05 and r =-0.35 p <0.05, respectively). In addition the serum levels of FGF23 were significantly correlated with BMD at all femoral subregions (p <0.05). At month 12 a significant increase in HDL-cholesterol and HDL/LDL-cholesterol ratio was observed. Moreover at month 12 both zoledronate and ibandronate induced a reduction in IMT (-4.73% p<0.05; and -1.75% p=n.s. respectively). FGF23 serum levels showed a significant decrease with respect to baseline in both zoledronate (-40.2% p<0.01) and ibandronate (-31.2% p<0.05) groups. Our findings seem to support a crosstalking between bone and atherosclerotic lesions, however, further studies are warranted to confirm as to whether FGF23 may play an important role in this.

Gonnelli, S., Caffarelli, C., L., T., M. D., T.P., A., C., Campagna, M.S., et al. (2013). The Effects of Intravenous Aminobisphosphonates on Carotid Atherosclerosis could Be Influenced by the Changes in FGF23 Serum Levels. JOURNAL OF BONE AND MINERAL RESEARCH, 28.

The Effects of Intravenous Aminobisphosphonates on Carotid Atherosclerosis could Be Influenced by the Changes in FGF23 Serum Levels

GONNELLI, STEFANO;CAFFARELLI, CARLA;CAMPAGNA, MARIA STELLA;NUTI, RANUCCIO
2013-01-01

Abstract

Some, but not all studies have reported a positive effect of aminobisphosphonates on atherosclerotic lesions. However, no convincing explanations exist regarding this finding. Recently it has been reported that the levels of FGF23 are positively related to the progression of atherosclerosis and to the calcification of atherosclerosis plaque. Sixty postmenopausal osteoporotic women (mean age: 66.4 ± 7.6 years), not previously treated with drugs for osteoporosis and with normal levels of 25OHvitamin D, were randomly allocated to receive zoledronate 5 mg i.v. annually or ibandronate 3 mg i.v. every 3 months. At baseline and at month 12 we measured serum lipids, bone isoenzyme of alkaline phosphatase, parathyroid hormone, 25-hydroxy-vitamin D, the terminal fragment of collagen type 1, the fibroblast growth factor-23 (FGF23) and osteocalcin. Patients with impaired renal function were excluded from the study. Bone Mineral Density (BMD) at lumbar spine and at femur (neck and total sub regions) and total body were also measured (DXA method, Prodigy GE Lunar, USA). An ultrasound examination of carotid vessels was performed to assess intima-media-thickness (IMT), presence of plaque and the degree of calcification. Patients with atherosclerotic plaques were found to have significantly lower BMD values (p <0.05) than those without plaques. Serum levels of FGF23 were reduced in osteoporotic women who presented with carotid plaques but without reaching any statistical significance (26.6 ? 14.6 vs 18.9 ? 8.1 RU/ml). Also serum levels of osteocalcin were reduced in women with carotid plaques (4.3 ? 2.5 vs 4.7 ? 1.2 ng/ml; p=n.s.). Both FGF23 and osteocalcin were negatively correlate with IMT (r =-0.42 p <0.05 and r =-0.35 p <0.05, respectively). In addition the serum levels of FGF23 were significantly correlated with BMD at all femoral subregions (p <0.05). At month 12 a significant increase in HDL-cholesterol and HDL/LDL-cholesterol ratio was observed. Moreover at month 12 both zoledronate and ibandronate induced a reduction in IMT (-4.73% p<0.05; and -1.75% p=n.s. respectively). FGF23 serum levels showed a significant decrease with respect to baseline in both zoledronate (-40.2% p<0.01) and ibandronate (-31.2% p<0.05) groups. Our findings seem to support a crosstalking between bone and atherosclerotic lesions, however, further studies are warranted to confirm as to whether FGF23 may play an important role in this.
2013
Gonnelli, S., Caffarelli, C., L., T., M. D., T.P., A., C., Campagna, M.S., et al. (2013). The Effects of Intravenous Aminobisphosphonates on Carotid Atherosclerosis could Be Influenced by the Changes in FGF23 Serum Levels. JOURNAL OF BONE AND MINERAL RESEARCH, 28.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/45036
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo